. 3 Health Commission of New South Wales. Code of safe practice in clinical laboratories. Sydney, NSW: Health Commission of NSW, 1980. (Accepted 43June 1982) Clinical Microbiology Department, Royal Newcastle Hospital, Australia 2300 H K GHOSH, PHD, FRCPA, director Fatal pulmonary fibrosis occurring during treatment with cyclophosphamide Pulmonary fibrosis is an uncommon complication of drug treatment and has been reported in association with many cytotoxic drugs.' We describe two patients who developed pulmonary fibrosis while receiving cyclophosphamide for glomerulonephritis.
Case reports
Case 1-A 58-year-old man was admitted to hospital with rigors, anorexia, increasing dyspnoea, and a non-productive cough. For seven weeks he had been taking 100 mg cyclophosphamide and 30 mg prednisolone daily for a rapidly progressive glomerulonephritis, and his renal function had been improving (serum creatinine concentration 311 umol/l; 3-5 mg/100 ml).
Examination showed fever, a tachycardia of 100/min, crepitations at both lung bases, and a left-sided pleural rub. Radiography showed left-sided basal shadowing. Intravenous cefuroxime 750 mg twice daily was given after specimens had been taken for culture. One week later he became acutely unwell, with cyanosis, tachypnoea, intercostal indrawing, a tracheal tug, and increase in intensity of the pleural rub. Blood gas analysis yielded 
Comment
In both patients no evidence of an infective agent was obtained. Cultures of sputum, urine, and blood all gave negative results, as did serological studies for legionellae, aspergillus, and candida. Viral titres remained insignificant. Biopsy material obtained in both cases at bronchoscopy and open-lung biopsy showed widespread severe interstitial fibrosis, less pronounced in case 2. There were newly formed reticulin fibres, organising and organised intra-alveolar exudates, and florid regenerative proliferation of alveolar epithelial cells, which were large, occasionally multinucleated, and often bizarre. A moderate, rather focal interstitial infiltrate of lymphocytes and plasma cells was present (fig) . There was no evidence of malignancy, and staining for infective organisms, including Pneumocystis carinii, gave negative results. Necropsy in both cases showed diffuse pulmonary consolidation, histologically the same as that obtained at biopsy and considered to be similar to the fibrosis associated with busulphan treatment.2 In the absence of any evidence of infection we believe that the progressive fibrosis was secondary to cyclophosphamide treatment. This reaction has been reported with low total dosage of cyclophosphamide after short courses3 but to our knowledge not in association with the treatment of renal disease. Only three cases of pulmonary fibrosis in association with cyclophosphamide have been reported to the Committee on the Safety of Medicines. World wide, eight cases have been documented. Resolution, however, often followed withdrawal ofthe drug.34 The mechanism of the reaction remains unsolved.
